MerLion Pharmaceuticals is a biopharma company focusing on the research, development and commercialization of drugs for the treatment of serious bacterial infections.
MerLion is working primarily on developing Finafloxacin, which has been designated a Qualified Infectious Disease Product (QIDP), as a therapeutic option for the treatment of bacterial infections in the human health sector:
Xtoro:
Xtoro is a US FDA- and Health Canada-approved drug containing Finafloxacin for the treatment of ear infections.
Biodefense:
Finafloxacin is being developed as a medical countermeasure against biothreat agents.
cUTI:
Finafloxacin is an important candidate for treatment of cUTI (complicated Urinary Tract Infections) and other infections such as hospital acquired pneumonia, skin infections and intra-abdominal infections that are treated in the hospital.

• Ines Nemack